GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magenta Therapeutics Inc (NAS:MGTA) » Definitions » Total Current Liabilities

Magenta Therapeutics (Magenta Therapeutics) Total Current Liabilities : $4.03 Mil (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Magenta Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Magenta Therapeutics's total current liabilities for the quarter that ended in Jun. 2023 was $4.03

Magenta Therapeutics Total Current Liabilities Historical Data

The historical data trend for Magenta Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Magenta Therapeutics Total Current Liabilities Chart

Magenta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Current Liabilities
Get a 7-Day Free Trial 10.42 14.12 11.43 10.86 14.55

Magenta Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.26 12.92 14.55 5.98 4.03

Magenta Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Magenta Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=10.725+3.824
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=14.55

Magenta Therapeutics's Total Current Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=4.034+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=4.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Magenta Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Magenta Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Magenta Therapeutics (Magenta Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magenta Therapeutics Inc (NAS:MGTA) » Definitions » Total Current Liabilities
Comparable Companies
BCEL BOLT HARP CRIS ABVC ICCC LUMO CYT ACHV LTRN OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
100 Technology Square, 5th Floor, Cambridge, MA, USA, 02139
Website
https://www.magentatx.com
Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, MGTA-45 and others.
Executives
Peter Evan Harwin director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Tomas Kiselak director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Edward Carr officer: CHIEF ACCOUNTING OFFICER 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Ryan Savitz officer: CHIEF FINANCIAL OFFICER 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Lei Meng director 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Simrat Randhawa officer: Chief Medical Officer 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Avidity Partners Management Lp director 2828 N HARWOOD STREET, SUITE 1220, DALLAS TX 75201
Marino Garcia director, officer: CEO and President C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVENUE, SUITE 2012, NEW YORK NY 10170
Adam M Veness officer: See Remarks C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Moulder Leon O Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paula Soteropoulos director 49 WINONA STREET, PEABODY MA 01960
Jonathan Violin director 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Third Rock Ventures Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Michael Vasconcelles director C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140

Magenta Therapeutics (Magenta Therapeutics) Headlines

From GuruFocus

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights

By PurpleRose PurpleRose • 08-04-2022

Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

By sperokesalga sperokesalga • 03-31-2023

Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference

By Business Wire Business Wire • 01-05-2022

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger � MGTA, STSA, ROCC, CVT

By sperokesalga sperokesalga • 05-17-2023

MGTA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Magenta Therapeutics, Inc. Is Fair to Shareholders

By Business Wire Business Wire • 05-03-2023

Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights

By Business Wire Business Wire • 11-04-2021

Shareholder Alert: Ademi LLP investigates whether Magenta Therapeutics, Inc. has obtained a Fair Price in its transaction with Dianthus

By PRNewswire PRNewswire • 05-04-2023

Moore Kuehn Encourages MGTA, HSKA, RUTH and SYNH Investors to Contact Law Firm

By sperokesalga sperokesalga • 05-10-2023

Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial

By Value_Insider Value_Insider • 12-20-2022

Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety

By Stock market mentor Stock market mentor • 01-25-2023